Pascal Deschatelets - Jan 9, 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Stock symbol
APLS
Transactions as of
Jan 9, 2023
Transactions value $
-$503,565
Form type
4
Date filed
1/10/2023, 07:07 PM
Previous filing
Dec 30, 2022
Next filing
Jan 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $49.4K +18.5K +1.89% $2.67* 996K Jan 9, 2023 Direct F1
transaction APLS Common Stock Sale -$553K -12K -1.21% $46.08 984K Jan 9, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -18.5K -9.14% $0.00 184K Jan 9, 2023 Common Stock 18.5K $2.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from a 10B5-1 trading plan.
F2 This stock option was granted on 12/5/2013 and is fully vested.